公开(公告)号：US20210087194A1

公开(公告)日：2021-03-25

申请号：US17009215

申请日：2020-09-01

Applicant: Novartis AG

Inventor： Hao Wang ,  Jiong Ye ,  Bo Han ,  Dietmar Flubacher ,  Hans Stettler ,  Fabrice Gallou ,  Franck Mallet ,  Matthias Napp ,  Michael Haller

IPC: C07D487/04

Abstract: The present disclosure relates to a method of synthesizing imidazopyrrolidinone derivative, such as compound of formula (I), or a solvate including hydrate thereof, or a co-crystal thereof, and/or intermediates thereof, their use as pharmaceuticals and the use of intermediates.

公开(公告)号：US10507201B2

公开(公告)日：2019-12-17

申请号：US16289612

申请日：2019-02-28

Applicant: NOVARTIS AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Pascal Furet ,  Diana Graus Porta ,  Carolina Haefliger ,  Bo Han ,  Thomas Knöpfel ,  Catherine Leblanc ,  Lv Liao ,  Robert Mah ,  Masato Murakami ,  Pierre Nimsgern ,  Michael Palmer ,  Dale Porter ,  Sebastien Ripoche ,  Can Wang ,  Youzhen Wang ,  Andreas Weiss ,  Jing Xiong ,  Xianglin Zhao

IPC: A61K31/475 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55 ,  A61P35/00 ,  A61K31/4375

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

公开(公告)号：US20190337952A1

公开(公告)日：2019-11-07

申请号：US16462266

申请日：2017-11-20

Applicant: Novartis AG

Inventor： Hao Wang ,  Jiong Ye ,  Bo Han ,  Dietmar Flubacher ,  Hans Stettler ,  Fabrice Gallou ,  Franck Mallet ,  Matthias Napp ,  Michael Haller

IPC: C07D487/04

Abstract: The present disclosure relates to a method of synthesizing imidazopyrrolidi-none derivative, such as compound of formula (I), or a solvate including hydrate thereof, or a co-crystal thereof, and/or intermediates thereof, their use as pharmaceuticals and the use of intermediates.

公开(公告)号：US10130629B2

公开(公告)日：2018-11-20

申请号：US15561209

申请日：2016-03-23

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Jorge Garcia Fortanet ,  Pascal Furet ,  Diana Graus Porta ,  Nafeeza Hafeez ,  Bo Han ,  Thomas Knoepfel ,  Matthew J. LaMarche ,  Catherine Leblanc ,  Lv Liao ,  Robert Mah ,  Dale Porter ,  Can Wang ,  Markus Wartmann ,  Jing Xiong ,  Xianglin Zhao

IPC: A61K31/496 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377

Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.